USSTOCK.TODAY
Regular Market
Log in Sign up

Johnson & Johnson Announces Reduced Mortality Rates for HRPCI Patients Supported by Impella

Medical Device Network +1 · ·by G4L

JNJ Johnson & Johnson
$280.78 -0.47%
View chart & analysis →
  1. 1Johnson & Johnson reported reduced mortality rates for high-risk percutaneous coronary intervention (HRPCI) patients supported by the Impella heart pump through three clinical analyses.
  2. 2The TRI-GUARD-PCI analysis showed an all-cause mortality rate of 6.1% for TRI-GUARD-PCI patients over 30 days.
  3. 3Johnson & Johnson added Impella to its portfolio through the acquisition of Abiomed in 2022.

So what's the key point?

Results show that mortality rates for patients using Johnson & Johnson's heart pump have decreased. This shows that the product acquired by the company is helpful to patients.

Source Medical Device Network +1 · View original ↗

Related 3-line summaries

Healthcare sector records largest gap against tech stocks in 25 years BeInCrypto · 53m agoFour companies remaining resilient in a rising interest rate environment The Motley Fool · 3d agoJohnson & Johnson's Incubator Model Performance and Strategic Shifts Pharma Voice · Nov 2
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news